| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ezra E Cohen | Q38641744 |
| P2093 | author name string | Edgardo S Santos | |
| Luis E Raez | |||
| Belisario A Arango | |||
| Cesar A Perez | |||
| P2860 | cites work | Hsp90: a specialized but essential protein-folding tool | Q24291482 |
| Thalidomide is an inhibitor of angiogenesis | Q24563363 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors | Q27619648 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results | Q28262507 | ||
| Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells | Q28277030 | ||
| Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma | Q28286125 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer | Q29615649 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Alteration of nucleosome structure as a mechanism of transcriptional regulation | Q29620047 | ||
| Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. | Q33296950 | ||
| Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers | Q33381378 | ||
| Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma | Q33381498 | ||
| Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer | Q33710562 | ||
| Histone deacetylases, transcriptional control, and cancer | Q33926323 | ||
| Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer | Q33984845 | ||
| Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells | Q33998266 | ||
| Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group | Q34013456 | ||
| Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis | Q34080215 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Molecular sequelae of proteasome inhibition in human multiple myeloma cells | Q34393832 | ||
| From the cradle to the grave: molecular chaperones that may choose between folding and degradation | Q34400939 | ||
| Vascular endothelial growth factor: basic science and clinical progress | Q34549887 | ||
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer | Q34560988 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma | Q34572289 | ||
| Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors | Q34635836 | ||
| Motesanib diphosphate in progressive differentiated thyroid cancer. | Q34791480 | ||
| A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer | Q34898930 | ||
| Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. | Q34989774 | ||
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. | Q35124840 | ||
| Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa | Q35212601 | ||
| Epigenetic targets in hematopoietic malignancies | Q35551110 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| The proteasome: a suitable antineoplastic target | Q35762448 | ||
| Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features | Q35787996 | ||
| BRAF mutation in thyroid cancer | Q36157661 | ||
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 | ||
| Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. | Q37068863 | ||
| Phase II trial of sorafenib in advanced thyroid cancer | Q37121708 | ||
| Phase II trial of sorafenib in metastatic thyroid cancer | Q37158278 | ||
| Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies | Q37534993 | ||
| A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. | Q37718291 | ||
| Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines | Q38426571 | ||
| Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer | Q38461485 | ||
| Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo | Q40227787 | ||
| Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro | Q40254257 | ||
| Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations | Q40266118 | ||
| Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells | Q40339240 | ||
| Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. | Q40343007 | ||
| Novel histone deacetylase inhibitors in the treatment of thyroid cancer | Q40422202 | ||
| Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells | Q40483365 | ||
| Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells | Q40527012 | ||
| 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels | Q40548638 | ||
| Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. | Q40570492 | ||
| Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells | Q40590583 | ||
| Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells | Q40592037 | ||
| Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors | Q40682401 | ||
| Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene | Q40928364 | ||
| An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. | Q42798763 | ||
| Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report | Q43775906 | ||
| Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes | Q43874043 | ||
| Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways | Q43935098 | ||
| Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor | Q44119192 | ||
| The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications | Q44211035 | ||
| MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma | Q46379055 | ||
| Survival and death causes in differentiated thyroid carcinoma. | Q46786638 | ||
| A phase II study of gefitinib in patients with advanced thyroid cancer. | Q46912384 | ||
| BRAF is a therapeutic target in aggressive thyroid carcinoma. | Q46988427 | ||
| Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. | Q53471245 | ||
| A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. | Q53606326 | ||
| Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. | Q54323561 | ||
| A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. | Q54420344 | ||
| A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies | Q61889849 | ||
| Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma | Q77294313 | ||
| Tyrosine kinases as targets for cancer therapy | Q80367757 | ||
| A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma | Q80500352 | ||
| Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas | Q80792406 | ||
| Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria | Q80873624 | ||
| Increasing incidence of thyroid cancer in the United States, 1973-2002 | Q83310394 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 736-745 | |
| P577 | publication date | 2011-05-04 | |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Novel molecular targeted therapies for refractory thyroid cancer | |
| P478 | volume | 34 |
| Q36977417 | A phase I study of ABT-510 plus bevacizumab in advanced solid tumors |
| Q85823646 | Cell surface nucleolin interacts with CXCR4 receptor via the 212 c-terminal portion |
| Q35750569 | Clinical review: Pituitary carcinoma: difficult diagnosis and treatment |
| Q36565803 | First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report |
| Q26765085 | Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications |
| Q37921602 | Multikinase inhibitors: a new option for the treatment of thyroid cancer. |
| Q37238757 | New developments in the diagnosis and treatment of thyroid cancer |
| Q38089099 | Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer |
| Q90276315 | Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer |
| Q56504638 | Sorafenib and thyroid cancer |
| Q87543752 | Summary of proceedings of the second World Congress on Thyroid Cancer |
| Q39326839 | Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets |
| Q35803876 | Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report |
| Q38185691 | Vandetanib for the treatment of thyroid cancer: an update |
| Q37974855 | Well differentiated thyroid carcinoma: current treatment. |
Search more.